title: Encapsulation of Protein-Polysaccharide HIP Complex in Polymeric Nanoparticles.
abstract: The objective of the present study is to formulate and characterize a nanoparticulate-based formulation of a macromolecule in a hydrophobic ion pairing (HIP) complex form. So far, HIP complexation approach has been studied only for proteins with molecular weight of 10-20 kDa. Hence, we have selected bovine serum albumin (BSA) having higher molecular weight (66.3 kDa) as a model protein and dextran sulphate (DS) as a complexing polymer to generate HIP complex. We have prepared and optimized the HIP complex formation process of BSA with DS. Ionic interactions between basic amino acids of BSA with sulphate groups of DS were confirmed by FTIR analysis. Further, nanoparticles were prepared and characterized with respect to size and surface morphology. We observed significant entrapment of BSA in nanoparticles prepared with minimal amounts of PLGA polymer. Finally, results of circular dichroism and intrinsic fluorescence assay have clearly indicated that HIP complexation and method of nanoparticle preparation did not alter the secondary and tertiary structures of BSA.
authors: Division of Pharmaceutical Sciences, School of Pharmacy, University of Missouri-Kansas City, 2464 Charlotte Street, Kansas City, MO 64108-2718, USA.
authors: Ripal
authors: R
authors: Gaudana
authors: Varun
authors: V
authors: Khurana
authors: Ashwin
authors: A
authors: Parenky
authors: Ashim K
authors: AK
authors: Mitra
references: Macromol Biosci. 2010 Feb 11;10(2):139-46
references: 19637151
references: Eur J Pharm Sci. 2006 Nov;29(3-4):174-82
references: 16828267
references: Pharm Res. 2000 Oct;17(10):1159-67
references: 11145219
references: J Pharm Sci. 2008 Jul;97(7):2395-404
references: 17828756
references: J Pharm Sci. 2001 Feb;90(2):194-201
references: 11169536
references: J Pharm Sci. 2010 Jun;99(6):2557-75
references: 20049941
references: Int J Pharm. 2007 Feb 1;329(1-2):142-9
references: 17000065
references: Nat Rev Drug Discov. 2005 Apr;4(4):298-306
references: 15803194
references: Int J Pharm. 2000 Sep 15;205(1-2):23-34
references: 11000539
references: Biochemistry. 1990 Feb 6;29(5):1262-71
references: 2322561
references: Expert Opin Drug Deliv. 2009 Oct;6(10):1123-33
references: 19663629
references: Drug Dev Ind Pharm. 2009 Aug;35(8):959-68
references: 19274512
references: Colloids Surf B Biointerfaces. 2009 May 1;70(2):248-53
references: 19185474
references: J Microencapsul. 2011;28(1):10-20
references: 20939702
references: J Pharm Pharmacol. 2001 Feb;53(2):167-78
references: 11273012
references: J Microencapsul. 2010;27(6):471-8
references: 20113168
references: Langmuir. 2007 Feb 27;23(5):2714-21
references: 17249699
references: AAPS PharmSciTech. 2009;10(2):670-7
references: 19459052
references: Int J Pharm. 2007 May 4;336(1):58-66
references: 17174492
references: Cancer Chemother Pharmacol. 2004 Nov;54(5):441-8
references: 15490166
references: Pharm Res. 1998 Feb;15(2):188-93
references: 9523302
references: Crit Rev Ther Drug Carrier Syst. 2002;19(1):73-98
references: 12046892
references: J Pharm Pharmacol. 2001 Aug;53(8):1099-107
references: 11518019
references: Expert Opin Drug Deliv. 2009 Feb;6(2):177-86
references: 19239389
references: Pharm Res. 2010 Apr;27(4):544-75
references: 20143256